Barclays lowered the firm’s price target on AnaptysBio (ANAB) to $63 from $79 and keeps an Overweight rating on the shares. Following the spinoff, AnaptysBio is a pureplay royalty company with accelerating Jemperli cash flows and upside from ongoing GSK development programs, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio price target lowered to $60 from $90 at UBS
- AnaptysBio Completes First Tracks Spin-Off, Refocuses on Royalties
- AnaptysBio completes separation of First Tracks Biotherapeutics
- AnaptysBio price target raised to $95 from $67 at Piper Sandler
- AnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup